Oxford PharmaGenesis is pleased to be supporting cardiopulmonary resuscitation (CPR) initiatives by providing employees with training opportunities so that they are better equipped to help someone if they are having a cardiac arrest.

So far at the World Orphan Drug Congress Europe 2015, we have been treated to a whirlwind introduction to some of the successes and challenges in the field of rare and orphan diseases.

Our Managing Director, Chris Winchester, walked 115 km along the Ridgeway this weekend to raise money for rare disease research. He and schoolfriend Justin Brooker set off from Princes Risborough at 7:30 on Saturday morning, and arrived in Avebury 60 hours later bruised and battered but happy.

Oxford PharmaGenesis showcased a broad range of HealthScience services throughout the ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) meeting, held 7–10 October in Barcelona, Spain. ECTRIMS is the world’s largest annual international conference devoted to basic and clinical research in multiple sclerosis (MS), with this year’s edition attended by more than 9000…

Duchenne muscular dystrophy (DMD) is a progressive and ultimately fatal genetic muscle wasting disease that affects approximately 1 in 3500 newborn boys.1 A fault in the dystrophin gene prevents the production of the protein dystrophin, which is important for muscle structure and function.

The experience and insights of Oxford PharmaGenesis into founding its office in Basel are highlighted in a feature in the September issue of Director magazine (the publication of the UK Institute of Directors). The feature focuses on UK company expansion into Switzerland and includes quotes from an interview with Dr Richard White, Commercial Director of…